Adverse Events
| Adverse event | Grade 1–2 | Possible, probable, or definite attribution | Grade 3 | Possible, probable, or definite attribution |
| Highest toxicity grade* | 6 (60%) | 6/6 (100%) | 3 (30%) | 0/3 (0%) |
| Fatigue | 8 (80%) | 8/8 (100%) | 0 (0%) | NA |
| Anorexia | 2 (20%) | 2/2 (100%) | 0 (0%) | NA |
| Vomiting | 2 (20%) | 2/2 (100%) | 0 (0%) | NA |
| Alkaline phosphatase increased | 2 (20%) | 2/2 (100%) | 0 (0%) | NA |
| Hypoalbuminemia | 2 (20%) | 2/2 (100%) | 0 (0%) | NA |
| Upper respiratory tract infection | 2 (20%) | 0/2 (0%) | 0 (0%) | NA |
| Cholangitis | 0 (0%) | NA | 1 (10%) | 0/1 (0%) |
| Hyponatremia | 0 (0%) | NA | 1 (10%) | 0/1 (0%) |
| Pulmonary embolism | 0 (0%) | NA | 1 (10%) | 0/1 (0%) |
| Urinary tract infection | 0 (0%) | NA | 1 (10%) | 0/1 (0%) |
| Abdominal pain | 1 (10%) | 1/1 (100%) | 0 (0%) | NA |
| Anemia (hemoglobin) | 1 (10%) | 1/1 (10%) | 0 (0%) | NA |
| Blood total bilirubin increased | 1 (10%) | 1/1 (10%) | 0 (0%) | NA |
| Diarrhea | 1 (10%) | 0/1 (0%) | 0 (0%) | NA |
| Dysuria | 1 (10%) | 0/1 (0%) | 0 (0%) | NA |
| Nausea | 1 (10%) | 1/1 (100%) | 0 (0%) | NA |
| Platelet count decreased | 1 (10%) | 1/1 (100%) | 0 (0%) | NA |
| Supraventricular tachycardia | 1 (10%) | 0/1 (0%) | 0 (0%) | NA |
↵* Two of 10 patients died during study. Both deaths were deemed possibly attributable to treatment.
NA = not applicable.
Adverse events are according to CTCAE 4.0. Highest toxicity grade is highest toxicity grade each patient experienced during study. One patient did not experience any significant toxicity. There were no grade 4 adverse events. Data are numbers followed by percentages in parentheses.